These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 7852189)
41. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Sakai E; Rikimaru K; Ueda M; Matsumoto Y; Ishii N; Enomoto S; Yamamoto H; Tsuchida N Int J Cancer; 1992 Dec; 52(6):867-72. PubMed ID: 1459726 [TBL] [Abstract][Full Text] [Related]
42. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
43. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Milde-Langosch K; Ocon E; Becker G; Löning T Int J Cancer; 1998 Feb; 79(1):61-5. PubMed ID: 9495360 [TBL] [Abstract][Full Text] [Related]
44. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509 [TBL] [Abstract][Full Text] [Related]
45. High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Sugio K; Gazdar AF; Albores-Saavedra J; Kokkinakis DM Carcinogenesis; 1996 Feb; 17(2):303-9. PubMed ID: 8625455 [TBL] [Abstract][Full Text] [Related]
46. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651 [TBL] [Abstract][Full Text] [Related]
47. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779 [TBL] [Abstract][Full Text] [Related]
48. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Kiba T; Tsuda H; Pairojkul C; Inoue S; Sugimura T; Hirohashi S Mol Carcinog; 1993; 8(4):312-8. PubMed ID: 8280380 [TBL] [Abstract][Full Text] [Related]
49. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203 [TBL] [Abstract][Full Text] [Related]
50. p53 mutations in sporadic adrenocortical tumors. Ohgaki H; Kleihues P; Heitz PU Int J Cancer; 1993 May; 54(3):408-10. PubMed ID: 8509216 [TBL] [Abstract][Full Text] [Related]
51. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Suzuki M; Saito S; Saga Y; Ohwada M; Sato I Cancer Genet Cytogenet; 2000 Apr; 118(2):132-5. PubMed ID: 10748293 [TBL] [Abstract][Full Text] [Related]
52. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Dansonka-Mieszkowska A; Ludwig AH; Kraszewska E; Kupryjańczyk J Ann Hum Genet; 2006 Sep; 70(Pt 5):594-604. PubMed ID: 16907706 [TBL] [Abstract][Full Text] [Related]
53. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation. Garcia A; Bussaglia E; Machin P; Matias-Guiu X; Prat J Int J Gynecol Pathol; 2000 Apr; 19(2):152-7. PubMed ID: 10782412 [TBL] [Abstract][Full Text] [Related]
54. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734 [TBL] [Abstract][Full Text] [Related]
55. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298 [TBL] [Abstract][Full Text] [Related]
56. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Ramnani DM; Wistuba II; Behrens C; Gazdar AF; Sobin LH; Albores-Saavedra J Cancer; 1999 Jul; 86(1):14-21. PubMed ID: 10391558 [TBL] [Abstract][Full Text] [Related]
57. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer. Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449 [TBL] [Abstract][Full Text] [Related]
58. Analysis of K-ras codon 12 mutations and p53 overexpression in colorectal nodule-aggregating tumors. Kusaka T; Fukui H; Sano Y; Ueda Y; Chiba T; Fujimori T J Gastroenterol Hepatol; 2000 Oct; 15(10):1151-7. PubMed ID: 11106095 [TBL] [Abstract][Full Text] [Related]
59. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084 [TBL] [Abstract][Full Text] [Related]
60. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Kappes S; Milde-Langosch K; Kressin P; Passlack B; Dockhorn-Dworniczak B; Röhlke P; Löning T Int J Cancer; 1995 Feb; 64(1):52-9. PubMed ID: 7665249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]